Corticosteroid induced central serous retinopathy

Sreelakshmi S  Mohandas; Rincy Anna Reji; Dr. Varsha Dalal; Dr. AHMV Swamy

Sreelakshmi S Mohandas Pharm D Intern, Dept. of Pharmacy Practice, KLE College of Pharmacy Hubballi
Rincy Anna Reji Pharm D Intern, Dept. of Pharmacy Practice, KLE College of Pharmacy Hubballi
Dr. Varsha Dalal Assistant Professor, Dept. of Pharmacy Practice, KLE College of Pharmacy Hubballi
dalalvarsha59@gmail.com
Dr. AHMV Swamy Professor, Dept. of Pharmacy Practice, KLE College of Pharmacy Hubballi

Abstract

A 50 year old female patient with Rheumatoid Arthritis was under Steroid therapy from past 5 years, further she developed blurring of vision and appearance of black spot in her right eye. Her fundoscopy and OCT findings revealed features of central serous retinopathy. Steroid therapy was withdrawn abruptly as there was no other known cause for CSR. After 3 months of withdrawal her symptoms got resolved. Amelioration after withdrawal confirmed CSR was induced by steroid. Rechallenge was not possible as recurrent occurrence of CSR may lead to a permanent vision loss. Educating patients regarding the possible adverse effect of drugs may help them in early detection and thereby making them avail for the management without any delay. Utilization of steroids needs proper surveillance & concerns and reporting of ADR’s help to enhance patient’s health related quality of life.

Keywords: Central Serous Retinopathy, , Steroid Therapy, , Rheumatoid Arthritis, Adverse Drug Reaction, Patient Education

Downloads

Download data is not yet available.

References

Liew, G., Quin, G., Gillies, M., & Fraser-Bell, S. (2012). Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clinical & Experimental Ophthalmology, 41(2), 201-214. doi: 10.1111/j.1442-9071.2012.02848.x.

Hua, C., Buttgereit, F., & Combe, B. (2020). Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open, 6(1), e000536. doi: 10.1136/rmdopen-2017-000536.

Zamir, E. (1997). Central serous retinopathy associated with adrenocorticotrophic hormone therapy. Graefe's Archive For Clinical And Experimental Ophthalmology, 235(6), 339-344. doi: 10.1007/bf00937280.

Shah, S., Desai, M., Desai, C., & Dikshit, R. (2011). Steroid-induced central serous retinopathy. Indian Journal Of Pharmacology, 43(5), 607. doi: 10.4103/0253-7613.84985.

Abouammoh, M. (2015). Advances in the treatment of central serous chorioretinopathy. Saudi Journal Of Ophthalmology, 29(4), 278-286. doi: 10.1016/j.sjopt.2015.01.007

Nielsen, J., & Jampol, L. (2011). ORAL MIFEPRISTONE FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina, 31(9), 1928-1936. doi: 10.1097/iae.0b013e31821c3ef6.

Chin, E., Almeida, D., Roybal, C., Niles, P., Gehrs, K., & Sohn, E. et al. (2015). Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy. Clinical Ophthalmology, 1449. doi: 10.2147/opth.s86778.

Lotery, A., O'Connell, A., Harris, R., Sivaprasad, S., & Reeves, B. (2020). Eplerenone for chronic central serous chorioretinopathy – Authors' reply. The Lancet, 396(10262), 1557-1558. doi: 10.1016/s0140-6736(20)32321-7.